---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-014643"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:06:39.297083+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma reports Q2 FY2024 results; cash $59.5M, zero revenue, clinical data readouts expected H1 2024

## Summary
- Cash, cash equivalents and short-term investments of $59.5M at Dec 31, 2023, with no outstanding debt.
- Revenue zero for Q2 ended Dec 31, 2023 vs $32.7M prior year due to Kyowa Kirin agreement termination.
- R&D expenses fell to $3.9M in Q2 from $15.3M Q2 prior year, driven by zandelisib program wind-down.
- Expects initial safety/efficacy data for voruciclib (CDK9 inhibitor) and ME-344 (mitochondrial inhibitor) in first half of 2024.
- Cash used in operations was $29.5M for six months ended Dec 31, 2023, comparable to $29.1M prior period.

## SEC filing metadata
- accession: 0000950170-24-014643
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017024014643/0000950170-24-014643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017024014643/meip-20240213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-014643
- JSON: https://secwatch.observer/filing/0000950170-24-014643.json
- Plain text: https://secwatch.observer/filing/0000950170-24-014643.txt

## Key facts
- Earnings Releases
  Lite Strategy, Inc. reported financial results for second quarter ended December 31, 2023.
  - Period: second quarter ended December 31, 2023
  - Result: reported results
  source text: On February 13, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1262104/000095017024014643/0000950170-24-014643-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.